ValuEngine upgraded shares of Mallinckrodt (NYSE:MNK) from a sell rating to a hold rating in a report published on Monday, February 4th.
A number of other equities research analysts have also commented on MNK. Zacks Investment Research upgraded Mallinckrodt from a hold rating to a strong-buy rating and set a $21.00 price target on the stock in a research report on Tuesday, January 8th. Wells Fargo & Co set a $27.00 price objective on Mallinckrodt and gave the company a hold rating in a research report on Friday, December 7th. Piper Jaffray Companies set a $39.00 price objective on Mallinckrodt and gave the company a buy rating in a research report on Friday, December 7th. Berenberg Bank set a $23.00 price objective on Mallinckrodt and gave the company a sell rating in a research report on Wednesday, November 7th. Finally, Mizuho reiterated a hold rating and issued a $27.00 price objective on shares of Mallinckrodt in a research report on Tuesday, November 6th. Three equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Mallinckrodt currently has a consensus rating of Hold and a consensus target price of $31.44.
Mallinckrodt stock traded down $0.05 during trading hours on Monday, hitting $24.91. The stock had a trading volume of 1,796,708 shares, compared to its average volume of 1,115,416. Mallinckrodt has a fifty-two week low of $11.65 and a fifty-two week high of $36.65. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of 3.11, a price-to-earnings-growth ratio of 0.24 and a beta of 2.33. The company has a quick ratio of 2.05, a current ratio of 2.21 and a debt-to-equity ratio of 0.93.
Mallinckrodt (NYSE:MNK) last released its quarterly earnings data on Tuesday, February 26th. The company reported $2.18 earnings per share for the quarter, beating the consensus estimate of $1.98 by $0.20. The company had revenue of $834.90 million for the quarter, compared to analyst estimates of $681.45 million. Mallinckrodt had a return on equity of 9.60% and a net margin of 65.24%. The company’s revenue was up 5.4% compared to the same quarter last year. During the same period in the prior year, the company posted $2.01 EPS. On average, analysts expect that Mallinckrodt will post 8.08 earnings per share for the current fiscal year.
A number of institutional investors have recently modified their holdings of MNK. Bank of New York Mellon Corp raised its stake in Mallinckrodt by 3.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,093,463 shares of the company’s stock worth $20,404,000 after buying an additional 32,427 shares during the period. Northern Trust Corp raised its stake in Mallinckrodt by 90.5% during the 2nd quarter. Northern Trust Corp now owns 1,333,630 shares of the company’s stock worth $24,884,000 after buying an additional 633,697 shares during the period. United Services Automobile Association raised its stake in Mallinckrodt by 18.4% during the 2nd quarter. United Services Automobile Association now owns 19,432 shares of the company’s stock worth $363,000 after buying an additional 3,026 shares during the period. Atria Investments LLC acquired a new stake in Mallinckrodt during the 3rd quarter worth $392,000. Finally, Dorsey Wright & Associates acquired a new stake in Mallinckrodt during the 3rd quarter worth $1,558,000.
Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Mallinckrodt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt and related companies with MarketBeat.com's FREE daily email newsletter.